Introduction
Prostate cancer (CaP) is the most common noncutaneous malignancy in American men, with 218 890 new cases predicted in 2007, amounting to 27 050 deaths. 1 The introduction of prostate-specific antigen (PSA) screening has decreased mortality significantly over the past 20 years, but the use of PSA as a diagnostic serum marker is far from perfect. No one level of PSA is maximally sensitive and specific, which allows for both falsepositive and -negative results within 'normal' ranges. In intermediate ranges (4-10 ng ml À1 ), specificity is reported to be 20% with a sensitivity of 80%. 2 Thus, some argue that PSA screening allows for the excessive detection of insignificant cancer, which is invariably overtreated in the United States, while others maintain that a substantial number of cancer diagnoses are missed. Moreover, no single marker has been identified which indicates disease outcome.
There is a need for additional serum markers that correctly predict the significant presence and progression of CaP to avoid unnecessary biopsy or treatment, lower morbidity and unnecessary expense; and to better tailor management. A variety of diagnostic and prognostic markers have been sought in bodily fluids and histological specimens, but with little validation for clinical use. The ideal biomarker should be prostate specific; detectable in an easily accessible biological fluid, and be able to distinguish between normal, benign prostatic hyperplasia (BPH), prostatic intraepithelial neoplasia and cancerous prostate tissues. In addition, the marker should be measurable by a reproducible assay and should have sufficiently convincing correlative clinical data. Serum makers in particular are especially helpful because of the ease of availability and the absence of sampling error associated with tissue extraction. This review will examine the current status of serum biomarkers, illustrating their benefits and limitations as they pertain to the diagnosis and prognosis of CaP. We will summarize prospective markers from identified genes and molecules, including genetic modifications and autoantibodies, which display altered expression between benign and malignant disease and have the potential to supplement or fulfill the role of PSA. There are several biomarkers that appear to have considerable supportive data; however, for the purpose of this review we will discuss the following: chromogranin-A (CgA), human glandular kallikrein 2 (hK2), urokinase-type plasminogen activator (u-PA), transforming growth factor-b 1 (TGF-b 1 ), interleukin-6 (IL-6), prostate membranespecific antigen, prostate-specific cell antigen, a-methylacyl-CoA racemase (AMACR) autoantibodies, early prostate cancer antigen (EPCA), GSTP1 hypermethylation, sex hormones and sex hormone-binding globulin (SHBG) ( Table 1) . Other candidate markers, as well as the emerging field of proteomics, are also highlighted.
Selected serum markers

Markers of neuroendocrine differentiation
The prostate gland is composed of basal cells, exocrine cells expressing PSA and variable amounts of regulatory neuroendrocrine (NE) cells, 3 containing one or more neuropeptides such as CgA, neuron-specific enolase (NSE), calcitonin or somatostatin. 4 Differentiated NE cells have morphological features of cancer cells and often produce mixed epithelial and NE biological markers, apart from PSA. 5 Immunocytochemical studies have shown that androgen receptors are not expressed in these cells, suggesting that they may function independently of androgen regulation. 6 Previous studies have also revealed that increases in circulating CgA and NSE are associated with tissue NE differentiation. 5, 7 This process has become more widely recognized in the evolution of prostatic adenocarcinoma, though its biological and clinical significance remains unclear. 8 The most frequently detected peptide, CgA, has been studied as a diagnostic tool, but with little supporting Abbreviations: CpG, cytosine-phosphate-guanine; GSTP, glutathione S-transferase; PSA, prostate-specific antigen, RT-PCR, reverse transcriptase polymerase chain reaction; SELDI-TOF MS, surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.
PSA vs alternate serum markers ML Ramírez et al evidence for its use above conventional screening methods. Some report its utility in early diagnosis, particularly when used in conjunction with free/total PSA ratio; 9,10 however, others have found CgA does not accurately distinguish benign from malignant disease. 11 Similar controversy exists between CgA and tumor characteristics, [10] [11] [12] and CgA does not appear to be prognostic of disease recurrence after radical prostatectomy (RP) or radiation therapy. 13, 14 Inconsistencies may be explained by the fact that while most CaPs are characterized by NE differentiation, it is a transient and reversible process and thus NE markers may not always be detectable and a subset may have no NE differentiation. In addition, different patient cohorts and various methodological approaches may explain these observations. In fact, discrepancies in CgA measurements have been found between two commercially available assays used to distinguish CaP from BPH. 15 On the other hand, CgA may be more beneficial as a prognostic factor in patients with advanced CaP. The correlation with pathological stage, especially late-stage disease, has been more consistently demonstrated. 9, 16 CgA may predict response to chemotherapy, 17, 18 and as a marker of NE differentiation CgA has been shown to reflect androgen-independent disease even before evidence of PSA progression. 19, 20 Some have suggested that CgA velocity may be useful in predicting time to androgen independence after hormonal therapy and have indicated that treatments variably accelerate NE differentiation (intermittent androgen deprivation oantiandrogen only ocastration only ocombined androgen blockade). 16, 19 In the androgen-independent CaP patient, increased CgA levels appear to correlate with adverse outcomes and decreased overall survival, though levels indicative of a survival disadvantage are undefined (Table 2) . 21, 22 High serum levels of NSE have also been associated with adverse prognosis in metastatic CaP patients during androgen-suppression therapy, 23 but its predictive capability may be inferior to that of CgA. 9 Further evaluation of NE makers in monitoring and predicting prognosis may establish a practical use for these markers in hormone-refractory patients.
Human glandular kallikrein 2
Similar to PSA (hK3), hK2 is a serine protease with high levels of expression in the prostate. 24, 25 However, serum levels are only 1% of the concentration of PSA. Detection at low levels is therefore challenging, but the distinction is perhaps helpful in discriminating normal from cancerous tissue in which serum hK2 levels are more highly expressed. 26, 27 Data from Becker et al. 28 reveal that levels of hK2 are undetectable in healthy male controls, whereas concentrations are significantly higher in men with localized CaP than in men with BPH. When used in various combinations with free and total PSA, serum hK2 measurements have significantly improved discrimination of men with and without CaP by increasing both sensitivity and specificity. [29] [30] [31] Roobol et al. 32 assessed enhancement in predicting biopsy outcome contributed by hK2 to a base model incorporating digital rectal examination (DRE), transrectal ultrasound (TRUS), TRUS-measured gland volume, age, total PSA and having a previous biopsy. Data from this randomized PSA-based screening study of 559 men revealed that hK2 was a significant predictor of biopsy outcome (Po0.001) and improved the predictive capability of the model (AUC increased from 0.496 to 0.760).
Several more recent studies have also suggested a role for hK2 in predicting poorly differentiated, locally advanced disease and risk of biochemical recurrence before RP. 33, 34 In a recent abstract, Korets et al. 35 reported on the predictive value of hK2 in a case-controlled cohort of 146 men with biochemical recurrence following RP. In univariate analysis hK2 was found to be a significant indicator of biochemical recurrence, but it lost significance after considering other variables. Still, the addition of free PSA and hK2 to the standard predictive nomogram of total PSA, clinical stage and biopsy Gleason score increased the prognostic value of this model, particularly in men with PSAp10 ng ml
À1
. In another recent analysis, serum hK2, as opposed to PSA, retained significance in reflecting extracapsular extension, seminal vesicle invasion and biochemical recurrence in men with PSA o10 ng ml À1 (Table 3) . 36 In this prevalent subset of patients, hK2 may be useful in providing better risk assessment and indicating the need for more aggressive therapy.
Urokinase-type plasminogen activator
The plasminogen activation cascade is implicated in the degradation of the extracellular matrix and basement membrane, thereby facilitating angiogenesis, tumor cell growth and invasion during CaP progression. 37 The binding of u-PA to its cell surface receptor (u-PAR) increases its enzymatic activity and may also play a crucial role in metastasis of cancer cells. 38 Increased expression of u-PA in CaP tissue, which correlates with tumor grade and stage, has been demonstrated by Abbreviation: CgA, chromogranin-A. Adapted from Taplin et al.
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Data obtained from 321 patients with metastatic androgen-independent prostate cancer.
PSA vs alternate serum markers ML Ramírez et al immunohistochemical studies. 39 In vitro data also show u-PA expression to be inversely correlated with androgen receptor function. 40 Early studies of serum u-PA and u-PAR reveal an association with the presence and progression of CaP and patient prognosis. Miyake et al. 41 reported significantly elevated levels of both u-PA and u-PAR in patients with CaP, as opposed to healthy men or those with BPH, and in patients with advanced, as opposed to organconfined, disease. Serum concentrations also correlated significantly with overall survival rate. While subsequent studies have failed to confirm u-PAR can accurately distinguish CaP from BPH, evidence is in favor of its use in predicting progression. 42, 43 In a recent abstract, plasma levels of u-PA and u-PAR were reported to be associated with features of biologically aggressive CaP, disease progression after RP and the presence of metastasis. 44 Additional data reveal u-PAR overexpression may be related to tumor extraprostatic spread with significantly higher levels found in patients with pT3 vs pT2 disease. 43 Piironen et al. 45 introduced specific immunoassays for the quantification of the individual forms of u-PAR and suggested that measuring fragmented isoforms may reflect a more dynamic biochemical profile to better detect CaP. 46 An evaluation of these assays showed improved specificity and sensitivity of CaP detection when combined with total and percent free PSA (Table 4) . Steuber et al. 47 have since reinforced these data. Using regression analysis, preliminary data reveal u-PAR fragments are significant univariate and multivariate predictors of biopsy outcome, and the addition of these measurements significantly enhance diagnostic models consisting of PSA and patient age. This improved diagnostic accuracy was also seen in the subset of patients with PSA 2-9.99 ng ml À1 and normal findings on DRE (0.652 vs 0.715, P ¼ 0.039). Further validation is underway via a multi-institutional study.
Transforming growth factor-b 1 and interleukin-6
Transforming growth factor-b 1 is a pleiotropic regulatory growth factor, impacting cellular proliferation, chemotaxis, cellular differentiation, humoral and cell-mediated immunity, and angiogenesis. 48 Increased plasma TGF-b 1 concentrations have been found in patients with prostatic disease, but do not appear to accurately distinguish Abbreviations: PSA, prostate-specific antigen; tPSA, total PSA; %fPSA, %free PSA; u-PAR(I-III), urokinase-type plasminogen activator receptor (fragment types I-III).
between benign and malignant disease. 49, 50 Numerous studies demonstrate elevated serum levels in metastatic disease as compared to localized disease, indicating a role for TGF-b 1 in tumor progression. 48, 51 Moreover, TGF-b 1 has been shown to correlate with the extent of disease and biochemical recurrence post-prostatectomy. 48 Cytokines, such as IL-6, have multifunctional roles in the immune system, hematopoiesis and the acute-phase response. In CaP, IL-6 is reportedly produced by androgen-independent cancer cells, stimulating their growth while suppressing that of androgen-dependent cell lines. 55, 56 Multiple investigators describe elevated serum levels of IL-6 in metastatic cancer and hormonerefractory patients, [51] [52] [53] but few reveal a link with decreased patient survival. 57, 58 In a study of 191 patients with metastatic hormone-refractory CaP, George et al. 58 found serum IL-6 to be a prognostic indicator at multiple levels. In multivariate analysis adjusting for performance status, lactate dehydrogenase and PSA level, a median value of 4.80 pg ml À1 yielded a hazard ratio of 1.38 (95% CI, 1.01-1.89; P ¼ 0.043), and increasing the cut point to 13.31 pg ml À1 revealed increased prognostic significance with a hazard ratio of 2.02 (95% CI, 1.36-2.98; P ¼ 0.0005).
Transforming growth factor-b 1 and IL-6 show potential as prognostic indicators; however, clinical incorporation remains to be established. Kattan et al. 52 have developed an internally validated nomogram to predict the probability of biochemical progression after RP for localized CaP. With the addition of IL-6 and TGF-b 1 , predictive accuracy improved from 75 to 83%, indicating a role for these biomarkers in risk stratification.
Prostate-specific membrane antigen
Since its discovery in 1987, prostate-specific membrane antigen (PSMA) has been evaluated extensively as a diagnostic and prognostic marker although little is known of its functioning role. Despite significant expression in prostatic cells, detecting circulating PSMA by western blot or enzyme-linked immunosorbent assay (ELISA) is imprecise for quantitating proteins, and studies using these techniques have revealed mixed results. Initial reports indicated prognostic value of PSMA serum levels in select patients, 59 ,60 but further data showing additional value to current predictors have yet to be reproduced. 61, 62 In an effort to improve clinical staging, reverse transcriptase (RT)-PCR has been applied to detect PSMA-producing cells in the circulation. 63 However, too few institutions report a positive correlation for validation, 64, 65 and a current prospective study revealed no association between PSMA RT-PCR prevalence and pathological stage or biochemical relapse after RP. 66 In an attempt to better quantify circulating levels of PSMA, Xiao et al. 67 have employed a novel protein biochip immunoassay. Their initial results show that levels of serum PSMA in CaP patients are significantly different from those with BPH and in healthy men, even after stratification by age. Further testing is needed to validate the application of this assay.
Combined assays of more than one RT-PCR marker (that is, PSMA and PSA) have also been examined. Improvement in sensitivity and prediction of extracapsular extension has been reported by several authors, suggesting an advantage in detecting CaP micrometastases during clinical monitoring, but the clinical utility of combining tests remains questionable. 62, 63, 65 The use of PSMA as serum marker has limitations, since elevated levels have been observed in healthy men and with increasing age, a potential confounding factor within the population most frequently diagnosed with CaP. 68 To date, PSMA in tissue has been more encouraging as a diagnostic marker and therapeutic target than a circulating biomarker; however, as new antibodies to PSMA and improved assays are assessed, the value and efficacy of this tumor marker in circulation will be determined.
Prostate stem cell antigen
Prostate stem cell antigen (PSCA), a similar membrane glycoprotein expressed predominantly in the prostate, is a potential prognostic biomarker for several reasons. Expression of PSCA has been shown to be upregulated in the majority of CaPs, the extent of which correlates with Gleason score, advanced stage, metastasis and androgen-independent progression. [69] [70] [71] Moreover, complete androgen ablation and external beam radiation therapy have been shown to suppress PSCA prostate levels. 72, 73 While most studies involve tissue specimens, PSCA has also been detected in the serum using RT-PCR. In their analysis of circulating PSA-, PSMA-and PSCA-mRNA, Hara et al. 74 found PSCA to exhibit the highest disease specificity and independent prognostic value, but inferior sensitivity with no significant ability to differentiate malignant and benign disease. Though promising, definitive conclusions regarding PSCA as a serum marker have yet to be established, and until better methods are developed for detection and measurement, more evidence is in favor of its use in tissue.
a-Methylacyl-CoA racemase autoantibodies
Alpha-Methylacyl-CoA racemase (AMACR), an enzyme involved in fat metabolism, is reported to function independently of androgens as a growth promoter in CaP. 75, 76 The AMACR gene is overexpressed in CaP tissue at the mRNA and protein levels and is a highly specific tissue biomarker now used to assist pathological diagnosis. [77] [78] [79] In contrast, levels in serum have been unappreciable until recently. Zehentner et al. 80 successfully identified AMACR gene expression using a realtime RT-PCR assay and applied their findings to estimate tumor cell burden. Though higher levels were present in patients with CaP, AMACR was also commonly elevated in those with BPH and other urological disorders. Moreover, a range of values was observed in those with organ-confined CaP and BPH. Nonetheless, the addition PSA vs alternate serum markers ML Ramírez et al of the AMACR assay to serum measurements of PSA increased the diagnostic capability for organ-confined and metastatic CaP. Others suggest little utility for the AMACR gene as a marker in peripheral blood owing to poor specificity. 81 Potentially more useful, a humoral response to the AMACR tumor-associated antigen generates immunodetectable serum autoantibodies. 82 Data from Sreekumar et al. suggest AMACR autoantibodies may be useful in initial diagnosis, especially in combination with PSA screening. In patients with intermediate PSA levels (4-10 ng ml À1 ), they report significantly better sensitivity and specificity with AMACR antibodies than with PSA in distinguishing CaP patients from control subjects (77.8 and 80.6% vs 45.6 and 50%, respectively). Possible limitations may include the uncertainty of humoral response in patients with autoimmune disease and the production of AMACR autoantibodies from certain cancers other than prostate. 83 Testing is in progress to further evaluate the promising use of this serum biomarker.
Early prostate cancer antigen
Early prostate cancer antigen is a nuclear matrix protein, its name reflecting involvement of the nuclear transformations that occur in early CaP development. 84 Initially discovered in rat prostate tissue in 1991, 85 EPCA has since been detected in CaP precursor lesions, namely prostatic intraepithelial neoplasia and proliferative inflammatory atrophy, as well as CaP tissue. 86 Interestingly, no correlation exists between EPCA and pathological stage or Gleason score after RP, further supporting evidence that EPCA equates with early carcinogenesis. 84 It also appears to be absent in patients without CaP, but has been located to noncancerous areas adjacent to histologically proven cancer. 86 Moreover, EPCA has been detected in patients with initial negative biopsy that subsequently develop CaP, including those with BPH. 86, 87 Using a serum-based ELISA, Paul et al. 88 recently demonstrated the ability of EPCA antibodies to identify CaP. Among a cohort of 46 patients, 12 had CaP, 16 were healthy and 18 had other cancers, spinal cord injury or prostatitis. With a speculative cutoff value of 1.7 absorbance units, the sensitivity of the assay for CaP patients was 92% while the overall specificity was 94%. EPCA blood levels between the aforementioned groups were significantly different. Though validation with larger study populations is necessary, these early data show the potential diagnostic value of serum EPCA.
Another nuclear-associated protein, EPCA-2, has recently been identified as a potentially useful tumor marker. Using ELISA, Leman et al. 89 analyzed 330 serum samples for detection of EPCA-2 epitopes. Using a cutoff of 30 ng ml À1 , EPCA-2.22 epitope had 92% specificity among healthy men and those with BPH and 94% sensitivity for overall CaP with PSA 42.5 ng ml À1 (Table 5 ). EPCA-2 was also able to accurately distinguish between localized and extracapsular disease (Po0.0001) in comparison to PSA (P ¼ 0.05). Moreover, EPCA-2 levels before and after prostatectomy were significantly different (P ¼ 0.001). An update of this data with 189 additional serum samples further indicates the high specificity of EPCA-2 to differentiate patients with CaP from healthy men and those with other prostatic diseases, regardless of their PSA levels. 90 Further investigation will help to characterize the usefulness of EPCA-2 in the clinical setting.
GSTP1 hypermethylation
Numerous epigenetic alterations have been described in CaP. 91 The single, most frequent modification is reported to be hypermethylation of regulatory GSTP1 cytosinephosphate-guanine (CpG) islands, which encodes for p-class glutathione S-transferase (GSTP) and leads to inactivation seemingly early during prostate carcinogenesis. 92 Silencing of this 'caretaker' gene may affect prostatic cell susceptibility to genomic damage as a result of carcinogens or oxidative stress. 93 Several studies demonstrate high sensitivity and specificity for GSTP1 hypermethylation in high-grade prostatic intraepithelial neoplasia lesions and prostate adenocarcinomas, as well as correlations with tumor aggressiveness and recurrence after RP. 94, 95 Recent studies have demonstrated increased diagnostic specificity and sensitivity with GSTP1 in combination with various other methylated genes. 96, 97 GSTP1 hypermethylation is also expressed into the circulation, but studies have observed a wide range of PSA vs alternate serum markers ML Ramírez et al overall sensitivity (12-72%) and specificity (47.4-100%). [98] [99] [100] Discrepancies are most likely the result of differing detection methods and patient cohorts. Using fluorescent methylation-specific PCR assay, Goessl et al. 101 report a 93% detection rate among patients with T4N þ or M þ disease. More recently, Yang et al. 102 used a similar assay to detect the promoter region methylation status of three genes (GSTP1, RASSF1A and CDH1) in 73 men with CaP and 67 men with negative biopsies. The frequency of GSTP1 hypermethylation was 77% in cancer patients, significantly differing from those without disease (Po0.001). The diagnostic performance (true negative þ true positive/all men) of the three-gene panel was significantly better than that of GSTP1 alone (91.4 vs 75%, Po0.001). Using a threshold of 67% methylation, overall sensitivity and specificity was 86.3 and 82.1%, respectively. No relation of GSTP1 to pathological extent of disease, Gleason score or PSA was noted, making it a potential early and independent marker for the disease.
As opposed to other genetic alterations, detection of hypermethylation changes has several advantages, including simple amplification assays that can be used across all patient populations. With improvement of these assays and further controlled validation, GSTP1 hypermethylation may emerge as a helpful diagnostic marker. Currently, other modified genes are being evaluated in sera, as a defined profile of hypermethylated genes may be advantageous in diagnosis and monitoring disease progression. 103 
Sex hormones and sex hormone-binding globulin
Much biological data point toward the involvement of sex hormones with CaP pathogenesis. For instance, testosterone, which is essential for the development and the preservation of the prostate, can induce CaP in rodents if administered in high doses. 104 In addition, CaP does not arise in eunuchs 105 and is rarer in men with high levels of estrogen. 106 Interestingly, studies have shown a trend toward increased levels of androgens to decrease the risk of CaP and aggressive disease, but many have failed to reach significance. [107] [108] [109] [110] Severi et al. 111 used a case-cohort design to test this hypothesis in a large, prospective study with 8.7 years mean followup. High levels of testosterone were associated with reduced risk of aggressive CaP (P ¼ 0.03), classified as Gleason 47, stage T4, N þ or M þ disease, but not with less aggressive disease (P ¼ 0.40). Moreover, increased serum estradiol levels showed a trend toward lower CaP risk, but levels were not significant (P ¼ 0.07). Others have also revealed inconsistent data regarding estrogens. 107, 108 Several retrospective investigations have demonstrated an association between low pretreatment testosterone level and higher Gleason score, 112, 113 as well as with poor pathological findings after RP. 114, 115 Yano et al.
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found increased testosterone levels in patients with well-differentiated cancer as opposed to moderately or poorly differentiated (Po0.01), and higher levels in those with a Gleason score o7 vsX7 (P ¼ 0.03). Another investigation carried out in Japan identified a preoperative testosterone level o300 ng per 100 ml as an independent predictor of PSA failure after RP in patients with clinically localized CaP. 117 In a recent prospective study of 380 patients, Lane et al. 118 observed nonsignificant trends on multivariate analysis between low testosterone and predominant high-grade disease (P ¼ 0.084) and risk of biochemical recurrence (P ¼ 0.077). Without conclusive results, the clinical utility of serum testosterone remains limited. Likewise, several studies have shown a moderate decrease in CaP risk for high levels of serum SHBG, 107, 119 while others report insignificant results. 110, 111 Recently, Salonia et al. 120 examined the relationship of SHBG to CaP aggressiveness in patients undergoing RP. They found that patients with extracapsular extension had significantly higher levels of SHBG as compared to those with organ-confined disease, even after adjusting for PSA, clinical stage and biopsy Gleason grade (P ¼ 0.006). In a separate analysis, they identified SHBG as a significant univariate and multivariate predictor of lymph node invasion in patients who underwent extended pelvic lymph node dissection (Po0.001). 121 Bootstrap-corrected predictive accuracy of a nomogram based on clinical stage, PSA and biopsy Gleason scores increased from 74.9 to 83.9% with the addition of SHBG (Po0.001). With further validation, SHBG may prove to be a useful supplement to conventional prognostic factors.
Other markers
A myriad of other potential serum markers are currently being investigated (Table 6) . Caveolin-1, a regulatory molecule involved in cell to cell signal transduction, has been shown to be overexpressed in advanced CaP and may have prognostic value as a serum marker. 122 E-cadherin, b-catenin and matrix metalloproteinases are also involved in altered cell adhesion and cellular migration and appear to be promising biological markers associated with disease aggressiveness. 123, 124 Other potential protein biomarkers include inhibitors of metalloproteinases, 125 hepatocyte growth factor, 126 macrophage migration inhibitory factor, 127 progastrin-releasing peptide 128 and 50.8 kDa protein. 129 Additional growth factors, including insulin-like growth factor (IGF)-I, IGF-II and IGF-binding protein-3 (BP-3) have been implicated in the etiology of both benign and malignant disease. A few studies maintain that IGF-I and IGF-BP-3 add diagnostic specificity to current models using PSA-based markers, 130 while others have found its use limited for screening patients. 131 IGF-II was recently found to increase discrimination between BPH and CaP in 112 patients who underwent RP, as well as independently predict pathological stage. 132 Moderately elevated levels of serum leptin, a hormone involved in fat metabolism, have also been associated with the development of CaP. 133 Endoglin (CD105), an endothelial receptor for the TGFb superfamily, has been examined as a marker of ongoing angiogenesis during CaP progression. It may also be associated with facilitating metastatic growth in bone. 134 In a recent abstract, preoperative plasma endoglin levels were predictive of lymph node metastasis and disease progression in 425 patients undergoing RP. 135 Expression of other TGF receptors, namely epidermal growth factor receptor (EGFR) and human epidermal receptor 2 (HER2/nue), may correlate with disease progression and hormone-refractory disease. 136 A recent report revealed that serum EGFR measurements increased the PSA vs alternate serum markers ML Ramírez et al PSA vs alternate serum markers ML Ramírez et al ability to predict positive biopsies, and levels were significantly associated with those of u-PAR. 43 Detection of CaP-specific genes using variations of PCR methods has identified numerous biomarkers in tissue and bodily fluids. Expression of DD3
PCA3
, enhancer of zeste homolog gene 2, and hepsin, as well as activity of telomerase and p53 have all been described with good results. [137] [138] [139] [140] Quantitative assays for the detection of these genes in serum could serve as potentially valuable tools. Antibody array profiling has also identified possible serum markers, such as thrombospondin-1, that may differentiate between benign and malignant disease. 141 Increased antibody titers of antiproteasome and anti-huntingtin interacting protein-1 have been associated with the presence of CaP, 142, 143 and a serum ELISA against the latter yielded a specificity of 97% when combined with an anti-AMACR test. Other autoantibody signatures may increase the discriminatory power of a screening test and are currently being evaluated. 144 
Proteomics
Most researchers believe changes in serum protein composition reflect pathological changes in tissue. 145 Technological breakthroughs allowing profiling of the entire proteome show promise in the discovery of biomarkers. Matrix-assisted laser desorption/ionization time-of-flight is an advanced mass spectrometry technique that allows for protein identification through a host of molecular characteristics, including protein sequence, structure, heterogeneity, cleavage and posttranslational modifications. 146 Using a laser, proteins are sublimated and ionized out of a crystalline matrix; exact mass is then measured and signal intensity is detected. A downside of this technique is the extensive sample preparation needed, especially with complex solutions. Surfaceenhanced laser desorption/ionization time-of-flight (SELDI-TOF) overcomes this difficulty by separating protein mixtures based on chromatographic properties using a solid substrate-coated chip. 147 Residual contamination is removed by multiple washings, improving the ability to isolate trace amounts of multiple proteins for identification and quantification. An energy-absorbing molecule added to the chip array allows for laser desorption mass analysis to provide a molecular weight-based protein profile. Another approach uses photoaptamer chips consisting of single-strand nucleic acids selectively amplified in vitro. 148 Increased multiplicative specificity results from the replacement of T residues with bromodeoxyuridine, which yields ultraviolet-induced, covalently bound aptamer-protein complexes. Photoaptamer arrays are currently undergoing clinical assessment.
The most common of these methods, SELDI-TOF, appears to be a highly resourceful assay for identifying new potential biomarkers, quantifying known biomarkers and in detecting CaP-specific serum patterns. 149 Multiple studies have accurately distinguished benign from malignant disease with a range of sensitivities (83-100%) and specificities (85-100%), depending on the signature profile generated. [150] [151] [152] [153] Qu et al. 153 obtained 97% sensitivity and specificity using a boosted decision tree algorithm to analyze SELDI-TOF data, and a similar study performed in China yielded comparable sensitivity and specificity of 92 and 96.7%, respectively. Others have demonstrated favorable, but not such impressive, results. For example, proteomic profiles of 154 men with PSA 2.5-15 ng ml À1 were 100% sensitive and 67% specific for discriminating between positive and negative biopsies according to Ornstein et al.
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The biggest challenge seems to lie in developing standard, reproducible techniques. A multi-institutional, National Cancer Institute's Early Detection Research Network study is currently underway to substantiate the use of SELDI-TOF, and early data are extremely promising. Moreover, several potential markers are being evaluated in the P-mark project, which utilizes databases from two large, European CaP studies. 155 This 3-year study will use a combination of mass spectrometry tools to identify novel serum peptides and test their validity according to specific marker criteria.
Conclusions
There is substantial evidence for several novel serum markers to overcome the limitations of PSA. For instance, EPCA and hK2 have emerged as possible diagnostic factors, whereas others, such as CgA, IL-6 and TGF-b, may serve as prognostic predictors in certain populations. However, few biomarkers have been validated adequately and even fewer have been implicated in clinical practice. To date, inconsistent or insufficient data suggest that no single marker is likely to achieve the PSA vs alternate serum markers ML Ramírez et al desired level of sensitivity and specificity. More likely, a combination of markers or serum profile will improve the diagnostic accuracy of CaP screening, as well as the prognostic accuracy for influencing treatment. With the development of simple, reliable assays, these markers may soon gain validity and achieve acceptance in a practical setting (Table 7) . Prospective markers that are more clinically informative will allow individualization of therapeutic interventions. Finally, advanced proteomic techniques, as well as detection of gene modifications and autoantibodies, will contribute significantly to evolving strategies for optimal CaP detection and management.
